2、藥明生物 (02269.HK)：沖高破頂，能上30嗎？窩輪市場，投資者表示在27元有壓力，反手做put。 Simon:比較有趣的情況，正股升，窩輪市場的投資者則反手做空。暫時技術信號為"買入"，15個買入信號，沒有賣出信號。為什麼未有到"強力買入"呢？因 為還有9個中立信號。如果再上的話，首先看兩個阻力位28.5元和29.5元。低於30元水位。留意下周走勢的變化。 1、恆指：看多投資者表示在24000點入牛，如果跌24000就止損。看淡投資者則認為放量了，下周低開至24000，部署的熊證，收回價24888。也 有投資者持有熊證，收回價24600，止損離場，空倉過夜。 Simon：很多時候投資者對於市場的看法都是偏短線，不管窩輪還是牛熊證，投資部署都是偏短線，比如炒日內、或揸1-2日。所以我們用技術分析作為參 考，讓大家知道當前市況，作為短線走勢會如何？希望可以提供更多數據給短線交易的投資者，瞭解到目前市場的變化如何。比如恆指，最新的信號總結 為"買入"，看多信號為主。第一個阻力位在24600點附近，突破則上試25000點。投資者部署收回價在24888點左右的熊證，其實比較安全的，在兩個阻力位 之間。另外我 ...

個股推介 比亞迪電子(0285) 33.95 元 / 短線目標價：38.50 元 /16.7%潛在升幅 催化劑：i) 在美國解除 EDA 禁令和美越貿易協定於同日達成的背景 下，有利後續訂單交付外，料亦可舒緩市場對上游供應鏈單價、毛利率 壓力的憂慮； ii) 公司在AI伺服器、液冷散熱、移動機器人(AMR, Autonomous Mobile Robot)等賽道多點佈局，且與英偉達(NVDA US)具有多年的合作基礎， 有望帶來新的增長動能，後續深化合作為股價催化劑 估值：現價對應 FY25E/26E 13.2x/11.2x 預測市盈率(P/E)，其 FY26E 估值較 5 年均值低 1 個標準差(折讓 29%)，我們認為公司與北美客戶 的深化合作，其訂單佔比持續提升，有助舒緩 Android 客戶手機部件及 組裝業務壓力，加上業務及產品結構持續向高毛利非電子消費品領域 拓展，續有利估值修復 市場回顧 中港股市短期展望 恒指受制 24,700 點：中美在 5 月中旬於瑞士日內瓦經貿會談後發布聯 合聲明，雙方降低加徵關稅，互相保留加徵 10%關稅，美國對中國進口 貨品關稅將由 145%降至 30%，中國對美國進 ...

Core Viewpoint - China Ping An (02318.HK) shows strong market performance with significant buying interest, indicating a potential upward breakout in stock price [1][4]. Technical Analysis - The stock price increased by 4.34% on July 10, closing at HKD 51.65, with a trading volume of HKD 4.181 billion, reflecting active market buying [1]. - As of 10:35 AM, the stock price rose to HKD 53.45, marking a 3.48% increase [1]. - Technical indicators suggest a bullish trend, with the stock successfully breaking above the 10-day (HKD 50.33) and 30-day (HKD 48.34) moving averages, and remaining above the 60-day moving average (HKD 47.12) [1]. - The MACD indicator shows a bullish crossover, and multiple technical indicators are signaling a "strong buy" [1][4]. Support and Resistance Levels - Key support levels are identified at HKD 48.9 (Support 1) and HKD 47.9 (Support 2), with the first resistance level at HKD 53.6 (Resistance 1) and a potential challenge at HKD 55.3 (Resistance 2) [4]. - The RSI indicator is at 57, nearing the overbought zone, but has not yet issued a sell signal, indicating further upward potential with a 54% probability of price increase [4]. Derivative Products - Bullish derivative products such as Morgan Stanley Bull Certificate (53099) and Societe Generale Bull Certificate (68530) have shown strong performance, with two-day gains of 14% and 11% respectively [4][11]. - Recommended call options include UBS Call Option (16750) and Bank of China Call Option (16856), both with a strike price of HKD 60.71 and approximately 9x leverage [7]. - For put options, UBS Put Option (28275) and HSBC Put Option (28259) are attractive, with a strike price of HKD 50.13 and around 7x leverage [7]. Investment Strategy - Investors are advised to monitor volume changes closely; a sustained breakout above HKD 53.6 could initiate a new upward trend [4]. - The recommended bull certificates have a safety margin with a redemption price set at HKD 44.2, providing about 7x actual leverage, suitable for medium-risk investors [11].

每日港股評析 港股早晨快訊 2025 年 7 月 7 日星期一 2012-01- 17 市場回顧 中港股市短期展望 恒指受制 24,700 點：中美在 5 月中旬於瑞士日內瓦經貿會談後發布聯合 聲明，雙方降低加徵關稅，互相保留加徵 10%關稅，美國對中國進口貨 品關稅將由 145%降至 30%，中國對美國進口貨品將由 125%降至 10%， 為期 90 日。中美 6 月倫敦談判達框架協議，後續關注 90 日對等關稅寬 限期過後能否取得長期協議。以伊停火，惟其後雙方是否遵循協議，仍有 待觀察。中美貿談續缺乏進展，內地現階段加推經濟刺激方案的意願不大， 企業盈利改善有限，北水於高位流入速度放緩。恒指阻力料見於 24,700 點，相當於未來 12 個月預測市盈率 11 倍。 短期看好板塊 宏觀焦點 ➢ 特朗普稱已簽署12國關稅信件 今寄出； 中方對等反制 限制採購歐醫療器械 商務部：針對進口 在華歐企產 品不受影響； OPEC+加速增產同意8月增產54.8萬桶/日高於預期 考慮9月再增 產； 企業消息 中國飛鶴(6186)上半年業績預跌 全年股息總額不少於20億人民幣； 外圍市況展望 陳樂怡 tracy.chan@ ...

Core Viewpoint - AIA Group (01299.HK) shows significant bullish signs in its stock price, driven by multiple technical indicators improving simultaneously, suggesting potential trading opportunities for investors [1][4]. Technical Analysis - AIA's stock price is currently at HKD 69.35, with a decline of 4.15%. The 5-day volatility is at 3.2%, indicating a neutral range, while the trading volume reached HKD 1.902 billion, reflecting high market participation [1]. - The 10-day moving average (MA10) has risen to HKD 70.19, crossing above the 30-day (HKD 68.04) and 60-day (HKD 63) moving averages, forming a "golden cross" and indicating a potential mid-term upward trend [1]. - The stock price has established a clear support level below the first resistance at HKD 73.9. A successful breakout above this level could target HKD 76.2, while short-term support levels are at HKD 67.3 and HKD 69.6 [4]. Derivative Products Performance - Leveraged products related to AIA have shown significant amplification effects. For instance, HSBC's bull certificate (55603) and UBS's bull certificate (55450) recorded gains of 14%, maintaining a leverage ratio of approximately 5 times [1]. - Notably, UBS's call option (13504) surged by 22%, and Bank of China's call option (28665) increased by 24%, with leverage effects reaching 8-9 times, outperforming bull certificates [2]. Market Sentiment and Strategy - The overall technical indicators provide a strong buy signal, with a composite strength score of 16, indicating a bullish consensus among most indicators. The RSI is at 66, suggesting the upward momentum is still intact despite entering the overbought territory [4][7]. - The current market environment is favorable for price consolidation at high levels, with short-term investors considering derivative products for aggressive strategies. The volatility increase and market uncertainty make selecting appropriate call or bull certificates crucial for participating in potential upward movements while managing risks [7][8]. Options and Certificates - Among the available call options, the Bank of China's option (28665) has a leverage of 9.8 times with a strike price of HKD 73.15, while UBS's option (13504) has a leverage of 8.8 times with a slightly lower strike price of HKD 72.05. Both options are set to expire in September 2025, making them suitable for short to medium-term bullish strategies [8]. - In the bull certificate category, UBS's (55450) and HSBC's (55603) products have a redemption price of HKD 60, with actual leverage ratios of 5.3 and 5.5 times, respectively. These certificates are considered stable tools for participating in upward trends, especially if the stock price holds above the HKD 70 support level [8].

每日港股評析 港股早晨快訊 2025 年 7 月 4 日星期五 2012-01- 17 市場回顧 中港股市短期展望 恒指受制 24,700 點：中美在 5 月中旬於瑞士日內瓦經貿會談後發布聯合 聲明，雙方降低加徵關稅，互相保留加徵 10%關稅，美國對中國進口貨 品關稅將由 145%降至 30%，中國對美國進口貨品將由 125%降至 10%， 為期 90 日。中美 6 月倫敦談判達框架協議，後續關注 90 日對等關稅寬 限期過後能否取得長期協議。以伊停火，惟其後雙方是否遵循協議，仍有 待觀察。中美貿談續缺乏進展，內地現階段加推經濟刺激方案的意願不大， 企業盈利改善有限，北水於高位流入速度放緩。恒指阻力料見於 24,700 點，相當於未來 12 個月預測市盈率 11 倍。 短期看好板塊 宏觀焦點 ➢ 財新中國6月服務業PMI回落至50.6，遜預期； 內地6月新能源車零售增25%；商務部擬加強二手車出口工作指導； 暑假限玩遊戲27小時；工信部強調綜合治理光伏行業低價無序競爭； 畢馬威料今年新股集資額最多可達2,500億元； 港滙觸發弱方兌換保證，金管局兩度共接296億元沽盤； 美國6月非農職位增14.7萬個超預期， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CHINA LIFE INSURANCE COMPANY LIMITED 公告 關連交易 成立合夥企業 董事會宣布，本公司、中國核電及中俄核工業基金（各方均作為有限合夥人）擬與廣州 金宏及中核基金（各方均作為普通合夥人）訂立合夥協議，藉以成立合夥企業。合夥企 業全體合夥人認繳出資總額為人民幣1,501,000,000元，其中，本公司認繳出資額為人 民幣1,200,000,000元。國壽金石將作為合夥企業的管理人。 集團公司為本公司的控股股東，目前持有本公司約68.37%的已發行股本，為本公司的 關連人士。集團公司間接持有國壽金石的全部股權，而國壽金石持有廣州金宏的全部 股權，因而國壽金石及廣州金宏均為本公司的關連人士。因此，本次交易構成本公司 在上市規則第14A章下的關連交易。由於本次交易適用的一個或多個百分比率超過 豁免遵守獨立股東批准的規定。 國壽金石作為合夥企業的管理人所收取的管理費金額適用的所有 ...

1、恆指：看多投資者認為可以小註搏牛證，也有投資者認為議息之後指數下探23500-23000點。從走勢看，今日收市價剛好企穩在保利加通道中線23710點。不過日線 圖看走勢向下。信號總結為"賣出"，整體短期走勢偏弱。支持位上，可留意數據分析的23200點，22500點。 | 信號總結 | 賣出信號 中立信號 | 買入信號 | | --- | --- | --- | | 틀出 | ਹੈ ਕ | O | 3、比亞迪（01211）：股價在130元徘徊，是否會有技術性反彈？信號總結為"賣出"。短期從中線下跌回落，走勢偏弱。參考保利加通道底部121.4元，數據 系統分析的支持位在122元和115元。 | | | | 信號總結 | 賣出信號 中立信號 買入信號 | | | --- | --- | --- | | 賣出 | O | O | 2、美團（03690）：連續下跌，130元是否有支持？從走勢看，支持位在127.2元，有機會跌穿130元關口。第二支持位在121.7元。另外保利加通道底部在129 元，走勢比較偏弱。窩輪市場方面，觀察到有部分投資者在低位搏反彈，也有投資者認為觀察能否企穩130元再考慮部署衍生品。 5、金 ...

Core Viewpoint - China Life Insurance (02628.HK) is experiencing a strong upward trend in its stock price, currently at 17.16 HKD, reflecting a 1.06% increase, following a rebound from a short-term support level of 16.2 HKD [1] Technical Analysis - The stock price has surpassed all major technical moving averages, including the 10-day moving average at 16.4 HKD, the 30-day moving average at 15.63 HKD, and the 60-day moving average at 15.23 HKD, indicating a bullish structure [1] - The stock is approaching the first resistance level at 17.3 HKD, with a potential target of 18.3 HKD if this level is breached [2] - The recent volatility is reflected in a 6.8% fluctuation over five days, with an RSI index at 72, indicating a technical overbought condition [3] - The overall technical indicators are rated as "strong buy," with a signal strength of 16 points, supported by bullish momentum across all categories [3] - The MACD has completed a golden cross and maintains an expanding trend, supporting a continued upward pattern [3] - The price has successfully broken through the Ichimoku cloud, suggesting further upward potential in the coming weeks [3] Derivative Products Performance - On June 6, China Life's related structured products performed well, with a 2.76% increase in the underlying stock, leading to significant gains in derivatives [4] - The Societe Generale bull certificate (53998) led with a 15% increase, outperforming the underlying stock, showcasing the leverage advantage of bull certificates in rising markets [4] Investment Options - Current market conditions provide diverse investment options through China Life's related structured products, with call options offering a leverage of 4.1 times [7] - Bull certificates from HSBC (53706) and JPMorgan (53835) offer over 5 times actual leverage, with a buyback price set at 14 HKD [7] - For bearish strategies, Citigroup's bear certificate (56865) offers a leverage of 4.7 times, with a buyback price set at 20 HKD, providing a favorable risk-reward ratio [7] Summary - China Life is in a healthy upward phase with strong volume-price support and trend indicator resonance, but caution is advised due to potential overbought conditions and divergence risks [10]

| 信號總結 賣出 | | | --- | --- | | | 賣出信號 中立信號 買入信號 | 2、騰訊控股 (00700)：看空投資者認為回購都止不住跌，下試試495元，也有投資者認為下個支持470-450元。窩輪市場上，有投資者留意行使價736.5元的認 購證，表示產品跟跌不跟漲。 1、恆指：有投資者認為站不穩23300，直踩23000-22700，熊證過夜，收回價23678。同樣看淡的投資者認為下個月會見到22000以下，現在買熊還有1200點 贏，收回價在24300以上的安全。也有投資者表示引熊，下週23400，小註牛證夜。 Simon:恆指橫盤格局，目前技術信號總結為"賣出"。有10個賣出信號，7個買入信號和7個中立信號。恒指近三日波幅不大，只有1.9%，幅度有收窄。目前收 市價剛好在保利加通道中線，處於不上不落的情況，技術分析計算的是輕微偏淡。參與牛熊證的朋友，需要多點耐心。技術分析的支持位22700點。如果跌 穿則考驗第二個支持位22300點。小注搏熊證是合理的，不過注意從4月底開始，走勢一路維持在保利加通道的中線之上，有機會出現反彈。 Simon:從日線圖看，近期處於下跌趨勢。信號總結為"賣 ...